Open Access Gateway
Med Princ Pract 2009;18:360–363

Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?

Kebapcilar L.a · Bilgir O.b · Alacacioglu I.d · Payzin B.d · Bilgir F.c · Oner P.c · Sari I.c · Calan M.c · Binicier O.e
aDivision of Endocrinology and Metabolism, bDivision of Hematology and cDepartment of Internal Medicine, Bozyaka Training and Research Hospital, dDivision of Hematology, Department of Internal Medicine, Izmir Ataturk Training and Research Hospital,and eDepartment of Internal Medicine, Dokuz Eylul University, Izmir, Turkey
email Corresponding Author

 goto top of outline Key Words

  • Imatinib mesylate
  • Growth hormone deficiency
  • Chronic myeloid leukemia

 goto top of outline Abstract

Objective: The purpose of this study was to determinewhether or not imatinib mesylate therapy induces growth hormone deficiency (GHD). Subjects and Methods: Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the –1.8 cut-off level. Results: Of the 17 patients in the study, 12 (70%) had severe GHD (serum GH level <3 μg/l after GST). IGF-I SDSs and IGFBP-3 SDSs were below –1.8 in 12 patients (70%) and below –0.9 in 10 subjects (58%). Four of the 5 remaining subjects with IGF-I SDS >–1.8 showed insufficient GH response to L-dopa stimulation. Nine subjects (52%) had both severe GHD based on GST response and IGF-I SDS below –1.8. If an IGF-I SDS cut-off value l<–3 were used,5 out of 17 subjects (30%) would be classified as GH deficient. These same patients also showed severe GHD based on GST response. Conclusions: The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations.

Copyright © 2009 S. Karger AG, Basel

 goto top of outline References
  1. Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib mesylate. Pharmacol Rev 2003;55:401–423.
  2. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR: Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000;55:266–267.
  3. Anderson LL, Jeftinija S, Scanes CG: Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp Biol Med (Maywood) 2004;229:291–302.
  4. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067–2079.
  5. Boquete HR, Sobrado PG, Fideleff HL, Sequera AM, Giaccio AV, Suárez MG, Ruibal GF, Miras M: Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab 2003;10:4702–4708.

    External Resources

  6. Corneli G, Gasco V, Prodam F, Grottoli S, Aimaretti G, Ghigo E: Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. Pituitary 2007;10:141–149.
  7. Kwan AY, Hartman ML: IGF-I measurements in the diagnosis of adult growth hormone deficiency. Pituitary 2007;10:151–157.
  8. Pastural E, Takahashi N, Dong WF, Bainbridge M, Hull A, Pearson D, Huang S, Lowsky R, DeCoteau JF, Geyer CR. RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. Oncogene 2007;26:1586–1594.
  9. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Stephens PA: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006;91:1621–1634.
  10. Oliveira MR, Ohnuma L, Bendit I, Dorlhiac-Lacer P, Giannella-Neto D: Interferon-α therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. Leuk Res 2001;25:711–717.
  11. Celniker AC, Chen AB, Wert RM Jr, Sherman BM: Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469–476.
  12. Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, Sanmartí A: Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 2008;68:942–950.
  13. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–916.

 goto top of outline Author Contacts

Levent Kebapcilar
Division of Endocrinology and Metabolism
Department of Internal Medicine, Bozyaka Training and Research Hospital
123/4 Street No: 10 A flat: 4, TR–35340 Izmir (Turkey)
Tel. +90 50 5448 2857, Fax +90 238 4038, E-Mail

 goto top of outline Article Information

Received: October 12, 2008
Revised: November 23, 2008
Published online: July 31, 2009
Number of Print Pages : 4
Number of Figures : 0, Number of Tables : 1, Number of References : 13

 goto top of outline Publication Details

Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)

Vol. 18, No. 5, Year 2009 (Cover Date: August 2009)

Journal Editor: Owunwanne A. (Kuwait)
ISSN: 1011-7571 (Print), eISSN: 1423-0151 (Online)

For additional information:

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (, applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.